Caleb Rans, PharmD, Author at Rheumatology Advisor - Page 2 of 2

Caleb Rans, PharmD

All articles by Caleb Rans, PharmD

No Difference in Malignancy Risk With Tocilizumab vs TNFis, Abatacept in RA

Researchers found that there was no difference in the incidence of malignancy in patients with rheumatoid arthritis who switched from biologic disease-modifying antirheumatic drugs or tofacitinib to tocilizumab compared with patients who used abatacept or a different tumor necrosis factor inhibitor, except in instances of nonmelanoma skin cancer.

Next post in Rheumatoid Arthritis Advisor